-
公开(公告)号：EP2585454A1
公开(公告)日：2013-05-01
申请号：EP11728247.5
申请日：2011-06-23
申请人： Novartis AG
发明人： MADERA, Ann Marie , POON, Daniel , SMITH, Aaron
IPC分类号： C07D417/04 , A61K31/506 , A61P35/00
CPC分类号： A61K31/506 , A61K31/4439 , A61K45/06 , C07D413/04 , C07D417/04 , A61K2300/00
摘要： The present invention provides compounds of Formula (I): wherein R
1 , R
2 , R
3 , and X are as defined herein. The compounds of Formula (I) and pharmaceutical compositions thereof are useful for the treatment of cancer, and B- Raf-associated diseases.-
公开(公告)号：EP1984350A1
公开(公告)日：2008-10-29
申请号：EP07716906.8
申请日：2007-01-22
申请人： NOVARTIS AG
发明人： BURGER, Matthew , NI, Zhi-jie , PECCHI, Sabina , ATALLAH, Gordana , BARTULIS, Sarah , FRAZIER, Kelly , SMITH, Aaron , VERHAGEN, Joelle , ZHANG, Yanchen , WAGMAN, Allan , NG, Simon , PFISTER, Keith , POON, Daniel , LOUIE, Alicia , PICK, Teresa , BARSANTI, Paul , IWANOWICZ, Edwin , FANTL, Wendy , HENDRICKSON, Thomas , KNAPP, Mark , MERITT, Hanne , VOLIVA, Charles , WIESMANN, Marion , XIN, Xiahua
IPC分类号： C07D401/04 , C07D401/14 , C07D405/12 , C07D405/14 , C07D417/12 , A61K31/506 , A61P35/00
CPC分类号： C07D401/04 , C07D401/14 , C07D405/12 , C07D405/14 , C07D417/12
摘要： Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof ; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.
-
公开(公告)号：EP3299367A1
公开(公告)日：2018-03-28
申请号：EP17190132.5
申请日：2014-03-13
申请人： Novartis AG
发明人： AVERSA, Robert John , BARSANTI, Paul Andrew , BURGER, Matthew , DILLON, Michael Patrick , DIPESA, Alan , HU, Cheng , LOU, Yan , NISHIGUCHI, Gisele , PAN, Yue , POLYAKOV, Valery , RAMURTHY, Savithri , RICO, Alice , SETTI, Lina , SMITH, Aaron , SUBRAMANIAN, Sharadha , TAFT, Benjamin , TANNER, Huw , WAN, Lifeng , YUSUFF, Naeem
IPC分类号： C07D403/12
摘要： The present invention provides compounds of Formula (I)
as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.摘要翻译： 本发明提供如本文所述的式（I）的化合物及其盐，以及这些化合物用于治疗与Raf激酶活性相关的病症的治疗用途。 本发明进一步提供了包含这些化合物的药物组合物，以及包含这些化合物和治疗剂的组合物。
-
公开(公告)号：EP2970216A1
公开(公告)日：2016-01-20
申请号：EP14714134.5
申请日：2014-03-13
申请人： Novartis AG
发明人： AVERSA, Robert , BARSANTI, Paul A. , BURGER, Matthew , DILLON, Michael Patrick , DIPESA, Alan , HU, Cheng , LOU, Yan , NISHIGUCHI, Gisele , PAN, Yue , POLYAKOV, Valery , RAMURTHY, Savithri , RICO, Alice , SETTI, Lina , SMITH, Aaron , SUBRAMANIAN, Sharadha , TAFT, Benjamin , TANNER, Huw , WAN, Lifeng , YUSUFF, Naeem
IPC分类号： C07D403/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D213/74 , C07D213/75 , C07D233/88 , C07D401/04 , C07D401/12 , C07D403/04 , C07D237/20 , C07D405/04 , C07D405/12 , C07D239/42 , C07D241/20
CPC分类号： A61K31/5377 , A61K31/444 , A61K31/501 , A61K31/5375 , A61K31/541 , A61K45/06 , C07B59/002 , C07B2200/05 , C07D213/74 , C07D213/75 , C07D213/81 , C07D213/82 , C07D213/84 , C07D233/88 , C07D237/20 , C07D237/22 , C07D237/24 , C07D239/42 , C07D239/47 , C07D239/48 , C07D241/20 , C07D263/58 , C07D277/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D491/08 , C07D491/107 , C07D493/04 , C07D493/10 , C07D495/04 , C07D498/08 , C07D513/04
摘要： The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
摘要翻译： 本发明提供了本文所述的式（I）化合物及其盐，以及这些化合物治疗与Raf激酶活性相关的疾病的治疗用途。 本发明进一步提供包含这些化合物的药物组合物，以及包含这些化合物和治疗性助剂的组合物。
-
公开(公告)号：EP3299367B1
公开(公告)日：2019-12-25
申请号：EP17190132.5
申请日：2014-03-13
申请人： Novartis AG
发明人： AVERSA, Robert John , BARSANTI, Paul Andrew , BURGER, Matthew , DILLON, Michael Patrick , DIPESA, Alan , HU, Cheng , LOU, Yan , NISHIGUCHI, Gisele , PAN, Yue , POLYAKOV, Valery , RAMURTHY, Savithri , RICO, Alice , SETTI, Lina , SMITH, Aaron , SUBRAMANIAN, Sharadha , TAFT, Benjamin , TANNER, Huw , WAN, Lifeng , YUSUFF, Naeem
IPC分类号： C07D403/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D233/88 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/12 , C07D239/42 , C07D471/04 , C07D487/04 , C07D263/58 , C07D491/107 , C07D493/04 , C07D495/04 , C07D498/08 , C07D513/04 , A61K31/444 , A61P35/00
-
公开(公告)号：EP2970216B1
公开(公告)日：2017-11-01
申请号：EP14714134.5
申请日：2014-03-13
申请人： Novartis AG
发明人： AVERSA, Robert , BARSANTI, Paul A. , BURGER, Matthew , DILLON, Michael Patrick , DIPESA, Alan , HU, Cheng , LOU, Yan , NISHIGUCHI, Gisele , PAN, Yue , POLYAKOV, Valery , RAMURTHY, Savithri , RICO, Alice , SETTI, Lina , SMITH, Aaron , SUBRAMANIAN, Sharadha , TAFT, Benjamin , TANNER, Huw , WAN, Lifeng , YUSUFF, Naeem
IPC分类号： C07D403/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D213/74 , C07D213/75 , C07D233/88 , C07D401/04 , C07D401/12 , C07D403/04 , C07D237/20 , C07D405/04 , C07D405/12 , C07D239/42 , C07D241/20
CPC分类号： A61K31/5377 , A61K31/444 , A61K31/501 , A61K31/5375 , A61K31/541 , A61K45/06 , C07B59/002 , C07B2200/05 , C07D213/74 , C07D213/75 , C07D213/81 , C07D213/82 , C07D213/84 , C07D233/88 , C07D237/20 , C07D237/22 , C07D237/24 , C07D239/42 , C07D239/47 , C07D239/48 , C07D241/20 , C07D263/58 , C07D277/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D491/08 , C07D491/107 , C07D493/04 , C07D493/10 , C07D495/04 , C07D498/08 , C07D513/04
-
公开(公告)号：EP2118087A1
公开(公告)日：2009-11-18
申请号：EP08729174.6
申请日：2008-02-06
申请人： Novartis AG
发明人： PECCHI, Sabina , NI, Zhi-jie , BURGER, Matthew , WAGMAN, Allan , ATALLAH, Gordana , BARTULIS, Sarah , NG, Simon , PFISTER, Keith, B. , SMITH, Aaron , ZHANG, Yanchen , MERRITT, Hanne , VOLIVA, Charles
IPC分类号： C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , A61K31/5377 , A61P35/00
CPC分类号： C07D401/14 , C07D401/04 , C07D405/14 , C07D413/14
摘要： Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, auutoimmune and cardiovascular diseases.
-
公开(公告)号：EP1989201A1
公开(公告)日：2008-11-12
申请号：EP07757005.9
申请日：2007-02-14
申请人： NOVARTIS AG
发明人： NI, Zhi-jie , PECCHI, Sabina , BURGER, Matthew , HAN, Wooseok , SMITH, Aaron , ATALLAH, Gordana , BARTULIS, Sarah , FRAZIER, Kelly , VERHAGEN, Joelle , ZHANG, Yanchen , IWANOWICZ, Ed , HENDRICKSON, Tom , KNAPP, Mark , MERRITT, Hanne , VOLIVA, Charles , WIESMANN, Marion , LEGRAND, Darren Mark , BRUCE, Ian , DALE, James , LAN, Jiong , LEVINE, Barry , COSTALES, Abran , LIU, Jie , PICK, Teresa , MENEZES, Daniel
IPC分类号： C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04 , A61K31/437 , A61K31/5025 , A61K31/428 , A61P35/00
CPC分类号： C07D487/04 , C07D417/04 , C07D417/14 , C07D471/04
摘要： Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, phospholipid kinases, G-protein coupled receptors, and phosphatases.
-
公开(公告)号：EP2118087B1
公开(公告)日：2012-03-28
申请号：EP08729174.6
申请日：2008-02-06
申请人： Novartis AG
发明人： PECCHI, Sabina , NI, Zhi-jie , BURGER, Matthew , WAGMAN, Allan , ATALLAH, Gordana , BARTULIS, Sarah , NG, Simon , PFISTER, Keith, B. , SMITH, Aaron , ZHANG, Yanchen , MERRITT, Hanne , VOLIVA, Charles
IPC分类号： C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , A61K31/5377 , A61P35/00
CPC分类号： C07D401/14 , C07D401/04 , C07D405/14 , C07D413/14
摘要： Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, auutoimmune and cardiovascular diseases.
-
公开(公告)号：EP2590968A1
公开(公告)日：2013-05-15
申请号：EP11729624.4
申请日：2011-07-04
申请人： Novartis AG
发明人： BURGER, Matthew , DING, Yu , HAN, Wooseok , LINDVALL, Mika , NISHIGUCHI, Gisele A. , RICO, Alice , SMITH, Aaron , TANNER, Huw , WAN, Lifeng
IPC分类号： C07D407/04 , C07D407/14 , C07D417/14 , C07D491/04 , A61K31/444
CPC分类号： C07D417/14 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/541 , A61K45/06 , C07D405/14 , C07D407/04 , C07D407/14 , C07D491/04 , A61K2300/00
摘要： The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof, as further described herein. Also provided are formulations comprising compounds of formula I, and a method to use such compounds for treating a disease or condition mediated by Provirus Integration of Maloney Maloney Kinase (PIM Kinase), GSK3, PKC, KDR, PDGFRa, FGFR3, FLT3, or cABL.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.039 秒)
